Sublingual esketamine for PTSD. The same inflammatory pathways that drive PTSD also appear in autoimmune disease — an exploratory neuroimmune signal we are measuring in the pilot.
Project Lucid is developing the first FDA-regulated at-home sublingual esketamine for PTSD — a $3.5B market with no approved biologic and no novel mechanism approved in 25 years. The 50mg film (LTS Lohmann, Phase 1 PK complete) achieves parent-drug Cmax comparable to Spravato 56–84mg while targeting the neuroinflammatory substrate conventional pharmacotherapy leaves untreated. An exploratory neuroimmune biomarker panel runs alongside the pilot. Asset: 505(b)(2) pathway confirmed, IRB-ready Phase 1/2 open-label pilot (N=12), Q4 2026 enrollment in Dallas. Ask: $2.5M SAFE on $12M pre-money cap — funds trial execution, biomarker panel, at-home REMS concordance dataset, and IND filing. Near-term catalyst: first DSMB interim Q1 2027; final readout and 505(b)(2) IND Q4 2027, catalyzing a $15–25M Series A.
*Sertraline (1999) and paroxetine (2001) are the only FDA-approved PTSD medications. Both are 1990s SSRIs. No novel mechanism has been approved in over 25 years. Sources: FDA, SAMHSA, Grand View Research.
Existing pharmacotherapies — SSRIs, SNRIs, prazosin — address neurotransmitter balance but leave this inflammatory substrate largely untreated. That is a core reason 40–60% of PTSD patients fail to achieve remission.
3.6 million treatment-resistant PTSD patients have exhausted every approved option. The same cytokines (IL-6, TNF-α, IL-17, interferon α/β) are central to autoimmune biology — a convergence we measure as an exploratory signal in the pilot, not a second indication.
Passos et al. (2015). "Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression." JAMA Psychiatry, 72(2), 192–200. Meta-analysis of 20 studies, N>1,000.
Spravato (esketamine nasal spray) received FDA approval in 2019 for treatment-resistant depression — not PTSD. Its in-clinic model and $6,000–8,000/month price tag create a prohibitive access barrier. Meanwhile, unregulated compounded troches ($100–150/month, dissociative doses) fill the vacuum with no FDA path.
The gap between Spravato and unregulated troches is where Project Lucid lives: FDA-regulated, low-dose, at-home, and designed from the ground up for PTSD.
The competitive landscape shifted materially in August 2024, when the FDA rejected MDMA-assisted therapy for PTSD — citing data integrity concerns and functional unblinding limitations inherent to psychedelic trials. The rejection underscores investor demand for candidates with cleaner, placebo-controlled evidence packages. Ketamine’s RCT record in PTSD is precisely that.
The 50mg sublingual esketamine film (manufactured by LTS Lohmann) operates through two complementary mechanisms simultaneously — rapid neuroplasticity induction and direct anti-inflammatory action. Project Lucid’s clinical program is the first to test this film for PTSD with an integrated exploratory neuroimmune biomarker panel.
Durability comes from frequency — not dose. And the same mechanism that rewires trauma modulates IL-17, TNF-α, and interferon signaling — the targets of Skyrizi, Humira, and Cosentyx.
NMDA receptor antagonism triggers downstream BDNF release, promoting synaptogenesis in the prefrontal cortex and hippocampus within hours — not weeks.
Esketamine directly suppresses pro-inflammatory cytokines IL-6 and TNF-α — addressing the neuroinflammatory substrate that conventional PTSD treatments leave untreated.
Sublingual film achieves ~29% bioavailability with rapid Tmax (~19 min) — parent-drug Cmax comparable to Spravato 56–84mg intranasal — without requiring in-clinic administration after the first supervised dose.
| Dimension | Project Lucid | Spravato (J&J) | IV Ketamine Clinics | Compounded Troches |
|---|---|---|---|---|
| Delivery | Sublingual film | Nasal spray | Intravenous infusion | Sublingual troche (lozenge) |
| Active Ingredient | Esketamine (50mg) | Esketamine (56–84mg) | Racemic ketamine | Racemic ketamine (compounded) |
| Setting | At-home after first clinic dose | In-clinic only (2-hr monitoring) | In-clinic only (45–60 min infusion) | At-home, unsupervised |
| Dosing Frequency | 3×/week | 2×/week → 1×/week maintenance | Varies (1–2×/week) | Variable (prescriber-dependent) |
| PTSD Indication | Primary target | Not indicated (TRD only) | Off-label | Off-label, unregulated |
| Neuroimmune Mechanism | Core thesis: dual-pathway | Not positioned | Not positioned | Not positioned |
| Dose Level | Sub-dissociative | Can be dissociative | Often dissociative | Often dissociative |
| Cost Model | Designed for accessibility | ~$900/session (before insurance) | $400–800/infusion | $100–150/month (cash pay) |
| Reimbursement Target | Insurance-reimbursable target | Limited (specialty pharmacy) | Rarely covered | Not covered (no FDA path) |
The sublingual film is the therapeutic. The digital monitoring platform is what makes at-home administration safe, measurable, and scalable. This is the technology our patent protects.
All 12 doses administered under direct clinical supervision with 2-hour post-dose monitoring. Vitals, CADSS, and SpO₂ collected at every session. Establishes the baseline safety profile.
First doses in clinic, maintenance doses transition to at-home with real-time digital monitoring. The platform tracks vitals, mood, dissociation, and safety checkpoints — flagging alerts to the treating clinician before, during, and after each dose.
FDA-regulated at-home esketamine with continuous digital safety infrastructure. Remote vitals, real-time dissociation scoring, between-dose symptom tracking, telehealth check-ins, and automated safety escalation. Positioned as a psychiatric therapy with a reimbursement target comparable to Spravato.
Patent-pending: Digital Systems for Remote Administration and Monitoring of Sublingual Esketamine for PTSD (Provisional Serial Nos. 63/785,736; 63/799,047; 63/804,512). PCT international application filed April 2026.
Ketamine follows an inverted–U curve: too little is sub-therapeutic, too much is dissociative. Spravato’s fixed 56/84mg steps miss the optimum for many patients. Project Lucid is designed for dose individualization — 25mg tiles combine to deliver 25, 50, 75, 100, 125, or 150mg per session within a single label.
A differentiated, defensible label at Phase 3. Supported by Irfan-Husain et al. IV ketamine dose-response data.
Spravato’s REMS mandates in-clinic observation for every dose. Project Lucid’s platform captures HR, SpO₂, dissociation (CADSS), and symptom data remotely — designed to demonstrate non-inferiority to in-clinic observation and unlock an at-home label. Prior art for this class of monitoring (MindMed/definium SMS with wearable) has already cleared an FDA pre-submission.
Project Lucid is an IRB-ready Phase 1/2 open-label pilot — N=12 (up to 15 enrolled) — studying 50mg sublingual esketamine 3×/week for 4 weeks in adults with PTSD and a co-occurring inflammatory/autoimmune condition. CAPS-5 is the primary endpoint. Inflammatory biomarkers and disease activity are exploratory signals that may inform future research. Each milestone below represents an investor catalyst event.
Protocol LUCID-PTSD-2026-001 (Version 2.1) is IRB-ready. PTSD with an integrated exploratory neuroimmune biomarker arm. Includes digital monitoring feasibility component, pre-specified SAP with O’Brien-Fleming alpha-spending, and autoimmune flare management protocol. 66-page protocol with 4-member DSMB (including rheumatologist).
ActiveEnrollment of N=12 adults with confirmed PTSD (CAPS-5 ≥ 26) and co-occurring autoimmune disease (RA, SLE, IBD, psoriasis/PsA, MS, AS, or thyroid). Expanded biomarker panel (IL-6, TNF-α, IL-17A, IFN-α, IL-10, CRP, BDNF, ESR) + disease activity scores (DAS28-CRP, SLEDAI-2K, PASI, EDSS, etc.) + wearable device and app data collection begins. EQ-5D-5L quality of life baseline.
IA-1 (N=3 completers): Safety-only review — AE profile, cardiovascular trajectory, CADSS, autoimmune flares, digital monitoring compliance. IA-2 (N=6 completers): Safety + conditional efficacy — aggregate CAPS-5 signal, autoimmune disease activity trends, digital concordance from 72 sessions. O’Brien-Fleming boundary: p < 0.0054 for early efficacy signal. Non-binding futility if conditional power < 20%.
Complete N=12 dataset across all four domains. PTSD: CAPS-5 d ≥ 0.8 + ≥40% response → Phase 2 RCT. Exploratory neuroimmune signal: informs future mechanistic research; not a go/no-go for a separate program. Safety: 0 drug-related SAEs + mean CADSS < 10. Digital: HR/SpO₂ concordance + CADSS r ≥ 0.70 + detection sensitivity ≥ 90% → at-home monitoring validated. Tipping-point robustness confirmed.
505(b)(2) IND application filing for PTSD indication. Phase 2 RCT design (N=60–80) with integrated at-home digital monitoring arm. Out-licensing and Series A ($15–25M) discussions catalyzed by the PTSD pivotal readout. If the exploratory neuroimmune signal is confirmed, it informs future mechanistic research partnerships.
All dosing sessions include 2-hour post-dose digital monitoring with validated dissociation assessment (CADSS at 40 minutes) and vital sign tracking. Explicit discharge criteria gate home release. C-SSRS suicidality screening at every visit. DSMB review after the first 6 patients. Stopping rules for any serious adverse event. The safety protocol was designed to demonstrate clinical viability — not just regulatory compliance.
The case for Project Lucid is not speculative — it rests on a converging body of clinical, pharmacokinetic, and mechanistic evidence. Repeated IV ketamine 3×/week produces PTSD response rates of 67–77% with Cohen's d up to 1.9. The 50 mg SL OTF achieves parent-drug Cmax comparable to Spravato 56–84 mg. And at-home sublingual ketamine has a robust real-world safety record across 11,441 patients.
Clinical. Repeated 3×/week IV ketamine is RCT-validated for PTSD. Feder et al. (Mount Sinai, 2021) established a 67% response rate and Cohen’s d = 1.13 vs. midazolam. The 2025 follow-up combining ketamine with written exposure therapy extended this to d = 1.9 with 69% durable response at Week 12 — among the largest effect sizes reported in psychiatric pharmacotherapy.
Pharmacokinetic. The 50mg LTS Lohmann oral thin film (Dahan et al., 2022 Phase 1) delivers parent-drug S-ketamine Cmax ~96 ng/mL — bracketed by Spravato 56mg (72.5) and 84mg (101) intranasal. Heavy hepatic first-pass metabolism generates a 4.6× norketamine-to-ketamine ratio vs. 1.4–1.8× for intranasal, plus meaningful S-hydroxynorketamine absent in nasal delivery. The sublingual route is a feature, not a compromise.
Safety. The largest real-world dataset (Wolfson et al., 2023, N=11,441 at-home sublingual ketamine) showed adverse events 3–5% at average doses 7× the Project Lucid dose. Bozan et al. (2026) documented 129 esketamine sessions over 2.5 years with no serious adverse events. Mindbloom’s N=374 PTSD cohort showed 79% meaningful improvement.
Mechanistic. Wellington et al. (2025, OKTOP transcriptomics, N=23 PTSD patients) identified 1,154 differentially expressed genes on 6-week oral ketamine, with IL-17 (z=3.36), interferon α/β (z=4.0), and cytokine-storm (z=4.26) pathway modulation — the identical targets of Skyrizi, Cosentyx, Humira, and Actemra. This is the molecular rationale for measuring inflammatory biomarkers as an exploratory arm in the PTSD pilot.
The gap Project Lucid fills: sublingual esketamine efficacy specifically in PTSD. That is what LUCID-PTSD-2026-001 directly addresses.
Dallas-based psychiatrist and PTSD specialist who developed Project Lucid directly from clinical ketamine experience. Sponsor-Investigator of LUCID-PTSD-2026-001 — an IRB-ready Phase 1/2 open-label pilot of 50mg sublingual esketamine for PTSD with co-occurring autoimmune disease.
The clinical premise of Project Lucid sits at the intersection of three bodies of evidence that have not previously been connected: Feder et al.’s RCT-validated 3×/week IV ketamine protocol, Dahan et al.’s Phase 1 PK characterization of the 50mg SL OTF, and Wolfson et al.’s at-home safety dataset of N=11,441. The synthesis is Dr. Idell’s.
Protocol LUCID-PTSD-2026-001 is patent-pending (administration protocol and digital monitoring system), IRB-ready, and targeting Q4 2026 enrollment. Dr. Idell is the Sponsor-Investigator.
Dr. Mukesh Kumar, PhD, RAC
CEO & Founder, FDAMap — Washington, DC. 20+ years in FDA regulatory affairs. 150+ clinical trials across 34 countries. Confirmed 505(b)(2) pathway viability for Project Lucid.
Dr. Steven Idell, MD, PhD
Pulmonary & Critical Care Physician. Temple Chair in Pulmonary Fibrosis. 40 years of continuous NIH funding. Founder of Lung Therapeutics (acquired → Rein Therapeutics). Deep translational drug development expertise.
EMMES Corporation
Full-service CRO engaged for Phase 1/2 pilot study design. Specializes in Phase I–IV trials, biostatistics, pharmacovigilance, and FDA regulatory affairs. AI-enabled trial management.
Neurolivd
Rachel Wurzman, PhD (CEO) — neuroscientist, neuroethicist, and licensed clinical social worker. Jon Nelson (Chief Lived Experience Officer) — healthcare executive and mental health advocate. Neurolivd embeds lived experience into every stage of product development — from protocol design through commercialization. Project Lucid integrates the patient voice from day one, not as an afterthought.
A $3.5B PTSD market with no approved biologic, no novel mechanism approved in 25 years, and a 50% first-line treatment failure rate. Project Lucid is designed to fill that gap with a regulatory pathway confirmed, human PK data in hand, and an integrated exploratory neuroimmune biomarker panel that may generate mechanistic insights for future research.
PTSD patients carry 2× the rate of autoimmune disease (O’Donovan et al., 2015; N=666,269). Wellington et al. (2025) demonstrated that oral ketamine modulates the identical inflammatory pathways as leading autoimmune biologics — IL-17 signaling, interferon α/β, and cytokine storm pathways. Project Lucid’s Phase 1/2 enrolls patients with co-occurring PTSD and an inflammatory/autoimmune condition, using CAPS-5 as the primary endpoint and collecting inflammatory biomarkers as exploratory signals.
Primary CAPS-5 endpoint. 505(b)(2) IND pathway confirmed. Phase 2 RCT → NDA. Positioned alongside Spravato at ~$64K/year reimbursement.
IL-6, TNF-α, IL-17A, IFN-α, CRP, BDNF, and disease activity scores collected as exploratory endpoints. If confirmed, informs future mechanistic research. Not a go/no-go for a separate program.
The Phase 1/2 data is the primary catalyst. A confirmed PTSD efficacy signal drives the IND and Phase 2 RCT. A confirmed exploratory neuroimmune signal informs future mechanistic research partnerships.
| Project Lucid | Spravato® (J&J) | IV Ketamine Clinics | Compounded Troches | Autoimmune Biologics | |
|---|---|---|---|---|---|
| PTSD Indication | Phase 1/2 active | Not indicated | Off-label | Off-label, unregulated | Not applicable |
| Neuroimmune Biomarkers | Exploratory endpoints in PTSD pilot | Not collected | Not collected | Not collected | Indication-specific only |
| Integrated Biomarker Panel | Yes — exploratory neuroimmune arm | No | No | No | No (psychiatric comorbidity not addressed) |
| Route | Sublingual film (at-home target) | Intranasal (in-clinic REMS) | IV infusion (in-clinic) | Oral (unregulated) | IV infusion / SC injection |
| Digital Monitoring | Wearable + app (patent-pending) | None (clinician only) | None | None | None |
| Inflammatory Biomarkers | IL-6, TNF-α, IL-17A, IFN-α, IL-10, CRP, BDNF, ESR | Not collected | Not collected | Not collected | Indication-specific only |
| Reimbursement Target | ~$64K/yr (PTSD psychiatric therapy) | ~$64K/yr (TRD only) | $5–10K/yr (cash pay) | $1–2K/yr (cash pay) | $64–250K/yr |
| FDA Pathway | 505(b)(2) confirmed | Approved (TRD) | None (off-label) | None | BLA (each drug) |
| Pre-Specified Go/No-Go | 4 domains + tipping-point | N/A (approved) | N/A | N/A | Standard Phase 3 |
| At-Home Scalability | Designed for it — digital REMS path | Blocked by REMS † | Impossible (IV access) | Unregulated — no FDA path | SC self-inject only (no monitoring) |
| † Spravato’s REMS (Risk Evaluation and Mitigation Strategy) mandates in-clinic administration with 2-hour post-dose observation by a healthcare provider for every dose — a structural barrier to at-home scalability that cannot be removed without a new NDA supplement. The FDA rejected MDMA-assisted therapy for PTSD in August 2024 (Lykos Therapeutics), citing data integrity concerns and functional unblinding — eliminating the only other novel PTSD candidate with a home-adjacent delivery model. Project Lucid’s sublingual film, combined with the digital monitoring concordance dataset from Phase 1/2, is designed to be the first esketamine product to demonstrate non-inferiority of remote monitoring vs. in-clinic observation — the regulatory prerequisite for at-home FDA authorization. | |||||
No other clinical program is testing an NMDA antagonist for PTSD with an integrated exploratory neuroimmune biomarker panel. Project Lucid is the only trial designed to measure this inflammatory signal in a PTSD patient population.
Before a single patient is enrolled, the protocol locks in a tipping-point analysis that stress-tests the primary result. Missing data is imputed at progressively worse outcomes — from last-observed value through return-to-baseline and beyond — to answer: how wrong would we need to be for the finding to disappear?
These thresholds are locked in the protocol (Section 7.10.7) before enrollment begins — not chosen after seeing the data. Combined with an O’Brien-Fleming alpha-spending function and a pre-registered SAP, this is the analytical rigor investors and the FDA expect for an IND-enabling dataset.
Whether you're evaluating an investment or exploring a clinical collaboration, we welcome direct conversations.
Seed-stage funding opportunity. Supporting Phase 1/2 pilot completion, biomarker data collection, and IND preparation. Reach out to receive the full investor deck, protocol summary, and financial projections.
Academic medical center partnerships, site collaboration, and key opinion leader engagement. Trauma psychiatrists, psychopharmacologists, and drug delivery researchers are welcome to reach out about the science and study design.
